Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | FECH | P22830 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035842 | 0.85 | KDM4E (0.45) | CHEK1KDM4EFECHKCNH2KMT2A | |
| SCHEMBL2030233 | 0.82 | KDM4E (0.44) | CHEK1KDM4EFECHKCNH2KMT2A | |
| SCHEMBL6897387 | 0.76 | HSP90AA1 (0.46) | CHEK1KDM4EFECHKCNH2CDK5 | |
| SCHEMBL305454 | 0.75 | CHEK1 (0.46) | CHEK1KDM4EFECHKCNH2KMT2A | |
| SCHEMBL2034857 | 0.75 | KDM4E (0.47) | CHEK1KDM4EFECHKCNH2KMT2A | |
| SCHEMBL2037628 | 0.75 | CHEK1 (0.46) | CHEK1KDM4EFECHKCNH2KMT2A | |
| SCHEMBL2033435 | 0.74 | CHEK1 (0.46) | CHEK1KDM4EFECHKCNH2TSHR | |
| SCHEMBL305538 | 0.73 | KDM4E (0.42) | CHEK1KDM4EFECHKCNH2KMT2A | |
| SCHEMBL2036334 | 0.73 | CHEK1 (0.47) | CHEK1KDM4EFECHKCNH2KMT2A | |
| SCHEMBL2033685 | 0.73 | CHEK1 (0.53) | CHEK1KDM4EFECHKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379510-B1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS | ICOS CORP (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7067506-B2 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2005-11-03 | — | — | US | disclosed |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | CHEK1 1/4885KDM4E 2395/4885FECH 2044/4885 |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | CHEK1, PCNA, CHEK2 | CHEK1 1/4885KDM4E 2395/4885FECH 2044/4885 |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | CHEK1, PCNA, CHEK2 | CHEK1 1/4885KDM4E 2395/4885FECH 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.